Product Overview: Ultima AOD 9604
AOD 9604 is a synthetic peptide fragment corresponding to amino acids 176-191 of human growth hormone, developed by Metabolic Pharmaceuticals. This C-terminal fragment retains the lipolytic properties of the parent hormone without its growth-promoting effects, making it valuable for metabolic research studies. Researchers at Stroid UK Shop examine this compound’s unique receptor binding profile and stability characteristics in controlled laboratory environments. The peptide demonstrates selective activity at growth hormone receptors while lacking the mitogenic effects associated with full-length growth hormone, providing researchers with a distinct tool for investigating metabolic pathway modulation.
Laboratory Applications
Scientists investigate AOD 9604’s mechanism of action through various in-vitro assays and cellular studies. The compound’s selective receptor binding allows researchers to study lipolytic pathways without confounding growth effects. Studies focus on its interaction with beta-3 adrenergic receptors and its influence on adenylyl cyclase activity in adipocyte cell lines. Researchers in our AOD 9604 research category utilise this peptide to examine fat oxidation mechanisms and cellular energy metabolism. The compound’s stability profile makes it suitable for extended incubation studies, while its synthetic nature ensures batch-to-batch consistency for reproducible experimental results.
Technical Specifications
| Parameter | Specification |
|---|---|
| Purity | ≥98% (HPLC verified) |
| Molecular Weight | 1815.08 g/mol |
| Sequence | YLRIVQCRSVEGSCGF |
| Appearance | White lyophilised powder |
| Solubility | Water, saline solutions |
| Storage | -20°C, protect from light |
| Stability | 2+ years when stored properly |
Each vial contains precisely 5mg of AOD 9604 peptide, manufactured under strict quality control protocols by Ultima Pharmaceuticals. The lyophilised formulation ensures extended shelf life and maintains peptide integrity during storage. Researchers studying selective modulators and peptide compounds often incorporate AOD 9604 into comparative studies examining metabolic pathway selectivity.
Research Compliance
This AOD 9604 5mg preparation is manufactured exclusively for in-vitro research applications and laboratory studies. The compound is not intended for human consumption, therapeutic use, or any application outside controlled research environments. Researchers must ensure proper institutional oversight and follow established protocols for peptide handling and disposal. All studies should be conducted by qualified personnel in appropriate laboratory facilities with adequate safety measures and documentation procedures in place.
